-
Inside the Venezuelan prison meant to 'drive you insane'
-
Trump to tout deals, defend Iran war in UN speech
-
UK king braces as memoir by Diana's brother goes on sale
-
Sri Lanka to issue verdict in landmark Easter attack trial
-
No green light to lift EU sanctions on Russian oligarchs, talks to resume
-
Macron says talks with Trump on Red Sea, Ukraine 'constructive'
-
UK agrees support for Saudi in struggle with Houthis: reports
-
Green policies just good politics, says UK minister
-
EU foreign policy chief calls for continued sanctions on Russia
-
Bardot auction in Paris fetches nearly one million euros
-
Flights scrapped, evacuations urged as Typhoon Dujuan wallops Japan
-
No timeline on Daniels injury return, says Commanders coach
-
Fonseca to take break from tennis
-
British Columbia sues OpenAI in US court over Canada school shooting
-
A Cuban zoo, and its animals, in epic battle for survival
-
French star Batum retires after 18-year NBA career
-
Infantino proposes consulting federations to reform FIFA
-
Zidane leads first France training session
-
El Nino weather pattern enters record territory: scientist
-
Man shot by ICE agent in Texas detained with bullet inside him: lawyer
-
OpenAI calls for US to lead global effort on AI standards
-
California declares state of emergency ahead of El Nino
-
South African ostriches plucked alive for luxury fashion: report
-
South Africa arrests three more suspects, after nine women murdered
-
US networks halt Trump coverage in revolt over White House ban
-
Carse needs time away from England, says captain Brook
-
Paramount settles with US states to clear Warner Bros. mega-merger
-
NOWPayments Releases Cross-Chain Payout Data Revealing Key Performance Benchmarks Across TRON, BNB Chain, and Solana
-
Climate crisis a job for world leaders, not just activists: UK FM
-
British Museum bans photos of Bayeux Tapestry as crowds linger
-
US networks halt Trump coverage over White House ban
-
COP31 host says AI climate footprint to be a summit priority
-
French singer accuses Miley Cyrus of plagiarism
-
Berlin's far-left vote winners reject anti-semitism charges
-
EU fines Google 403 mn euros for location data breach
-
Mancini eager for 'new adventure' on Italy return
-
'Best is yet to come,' says De la Fuente after Spain extension
-
Mbappe says having Zidane as France coach 'like a film'
-
Why diesel prices are rising more than crude oil
-
Palmer, Rice out of England Nations League squad
-
COP31 host says AI's climate footprint to be a summit priority
-
German auto workers stage mass protests in bid to save jobs
-
Renewables hit record in 2025, but world must move faster: report
-
Embattled Merz vows to keep ruling for 'democratic future' of Germany
-
US media outlets to sue Trump administration after White House ban
-
Merz vows to keep ruling coalition together for 'democratic future' of Germany
-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
N.Fournier--BTB